Technical Analysis for PFE - Pfizer, Inc.

Grade Last Price % Change Price Change
grade A 34.57 2.76% 0.93
PFE closed up 2.76 percent on Monday, April 6, 2020, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Apr 28
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up
Historical PFE trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
New Uptrend Bullish 2.76%
Overbought Stochastic Strength 2.76%
Crossed Above 20 DMA Bullish 5.17%
Overbought Stochastic Strength 5.17%
Fell Below 20 DMA Bearish 8.88%
Narrow Range Bar Range Contraction 8.88%
NR7 Range Contraction 8.88%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians for Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation therapeutic and disease areas. The company's Specialty Care and Oncology segment provides human prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. Its Established Products and Emerging Markets segment offers human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions, as well as that are sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. The company's Animal Health segment offers products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products, and other non-pharmaceutical products. Its Consumer Healthcare segment provides non-prescription products in therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. has a strategic collaboration with CytomX Therapeutics, Inc. to develop and commercialize Multiple Probody drug conjugates in oncology. The company was founded in 1849 and is headquartered in New York, New York.
Health Biopharmaceutical Pharmaceutical Industry Pain Disease Medication Pharmaceutical Products Inflammation Neuroscience Alzheimer's Disease Pain Management Cnx Nifty Dietary Supplements Pulmonary Arterial Hypertension Major Depressive Disorder Hemophilia Anti Infectives Pfizer Erectile Dysfunction Glaxosmithkline Livestock Producers Cardiovascular Endocrine Disorders Lupin Limited Non Pharmaceutical Products

Is PFE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 44.5613
52 Week Low 27.88
Average Volume 36,011,439
200-Day Moving Average 37.38
50-Day Moving Average 34.48
20-Day Moving Average 31.62
10-Day Moving Average 32.01
Average True Range 1.55
ADX 24.73
+DI 26.57
-DI 18.54
Chandelier Exit (Long, 3 ATRs ) 30.52
Chandelier Exit (Short, 3 ATRs ) 32.53
Upper Bollinger Band 35.02
Lower Bollinger Band 28.22
Percent B (%b) 0.93
BandWidth 21.49
MACD Line -0.33
MACD Signal Line -0.94
MACD Histogram 0.6087
Fundamentals Value
Market Cap 205.6 Billion
Num Shares 5.95 Billion
EPS 1.37
Price-to-Earnings (P/E) Ratio 25.23
Price-to-Sales 4.06
Price-to-Book 3.64
PEG Ratio 2.40
Dividend 1.28
Dividend Yield 3.70%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.25
Resistance 3 (R3) 36.17 35.54 35.97
Resistance 2 (R2) 35.54 35.11 35.58 35.88
Resistance 1 (R1) 35.05 34.84 35.30 35.13 35.78
Pivot Point 34.42 34.42 34.54 34.46 34.42
Support 1 (S1) 33.93 33.99 34.18 34.01 33.36
Support 2 (S2) 33.30 33.72 33.34 33.26
Support 3 (S3) 32.81 33.30 33.17
Support 4 (S4) 32.89